摘要
目的:探讨雷贝拉唑钠四联方案治疗幽门螺杆菌(helicobacter pylori,Hp)阳性十二指肠溃疡的临床疗效和安全性。方法:选取2015年1月—2016年2月禹州市中心医院收治的Hp阳性十二指肠溃疡疾病患者118例作为研究对象,以随机数字表法分为观察组和对照组,每组59例。对照组患者给予"奥美拉唑+阿莫西林+克拉霉素+枸橼酸铋钾"四联疗法,观察组患者给予"雷贝拉唑钠+阿莫西林+克拉霉素+枸橼酸铋钾"四联疗法,两组患者均连续治疗2周。观察两组患者的临床疗效、Hp根除情况,比较两组患者不良反应发生情况的差异。结果:治疗后,观察组患者的总有效率为91.53%(54/59),明显高于对照组的76.27%(45/59);观察组患者Hp根除率为96.61%(57/59),明显高于对照组的81.36%(48/59),差异均有统计学意义(P<0.05);两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:"雷贝拉唑钠+阿莫西林+克拉霉素+枸橼酸铋钾"四联疗法治疗Hp阳性十二指肠溃疡的疗效显著,可有效根除Hp,不良反应小,安全性高。
OBJECTIVE ： To probe into the efficacy and safety of quadruple therapy of rabeprazole in treatment of helicobacter pylori （Hp） positive duodenal ulcer. METHODS： 118 patients with Hp positive duodenal ulcer admitted into Yuzhou City Central Hospital from Jan. 2015 to Feb. 2016 were selected and divided into observation group and control group via the random number table, with 59 cases in each group. The control group was treated with quadruple therapy of omeprazole, amoxicillin, elarithromycin and bismuth potassium citrate, while the observation group was given quadruple therapy of rabeprazole sodium, amoxicillin, clarithromycin and bismuth potassium citrate, both groups received a two-week continuous treatment. The clinical efficacy and Hp eradication were observed, and the incidence of adverse drug reactions of two groups was compared. RESULTS： After treatment, the total effective rate of the observation group （91.53%, 54/59） was significantly higher than that of the control group （76. 27%, 45/59） ; the rate of Hp eradication of observation group （96.61%, 57/59） was significantly higher than that of the control group （81.36%, 48/59）, with statistically significant difference （P 〈 0. 05）; there was no statistical significance in incidence of adverse drug reactions between two groups （P 〉 0.05 ）. CONCLUSIONS： The efficacy of quadruple therapy of rabeprazole sodium, amoxicillin, clarithromycin and bismuth potassium citrate in treatment of Hp positive duodenal ulcer is remarkable, with effective Hp eradication, less adverse drug reactions and high safety.
出处
《中国医院用药评价与分析》
2017年第6期785-786,789,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
